Want to see COSM full AI Analyst Report?
Top Page
Cosmos Holdings
(NASDAQ:COSM)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.20
▲(0.00% Upside)
Action:Reiterated
Date:08/19/26
The score is primarily pressured by weak financial quality—thin gross margins, significant operating/net losses, and negative operating/free cash flow—despite improving revenue and reduced debt. Technicals add further caution with the stock below major moving averages and a negative MACD. Valuation is hard to support due to negative earnings, and the recent equity-plan/preferred authorization improves flexibility but raises dilution risk.
Positive Factors
Revenue Growth
Sustained top-line expansion indicates growing product sales across pharmaceutical and nutraceutical channels, providing a foundation for operating leverage if Cosmos can improve pricing, mix, and distribution efficiency.
Negative Factors
Persistent Unprofitability
Thin gross profitability and substantial operating losses indicate that current distribution economics do not adequately cover the cost base. Without durable margin improvement, revenue growth may continue to generate limited shareholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained top-line expansion indicates growing product sales across pharmaceutical and nutraceutical channels, providing a foundation for operating leverage if Cosmos can improve pricing, mix, and distribution efficiency.
Read all positive factors
Cosmos Holdings (COSM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.73M
Dividend YieldN/A
Average Volume (3M)16.84M
Price to Earnings (P/E)―
Beta (1Y)2.29
Revenue Growth29.75%
EPS Growth37.35%
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding62,078,396
10 Day Avg. Volume6,443,995
30 Day Avg. Volume16,844,547
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.82
Price to Sales (P/S)0.23
P/FCF Ratio-1.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cosmos Holdings Business Overview & Revenue Model
Company Description
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods....
How the Company Makes Money
Cosmos Holdings primarily makes money by selling pharmaceutical and nutraceutical products through its distribution and commercialization activities. Key revenue streams include: (1) product sales of pharmaceuticals (including branded and generic ...
Cosmos Holdings Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 73.73M | 65.27M | 54.43M | 53.38M | 50.35M | 56.24M |
| Gross Profit | 7.57M | 7.90M | 4.31M | 4.35M | 5.96M | 8.33M |
| EBITDA | -17.34M | -15.15M | -13.92M | -17.06M | -8.90M | -3.82M |
| Net Income | -24.39M | -19.14M | -16.18M | -18.54M | -13.83M | -7.96M |
Balance Sheet | ||||||
| Total Assets | 61.46M | 65.48M | 54.31M | 66.01M | 68.04M | 49.43M |
| Cash, Cash Equivalents and Short-Term Investments | 1.84M | 761.83K | 336.25K | 3.85M | 20.76M | 297.95K |
| Total Debt | 7.23M | 19.97M | 11.82M | 12.42M | 12.03M | 27.12M |
| Total Liabilities | 40.79M | 47.05M | 29.78M | 29.97M | 28.38M | 45.05M |
| Stockholders Equity | 20.67M | 18.42M | 24.53M | 36.04M | 39.66M | 4.38M |
Cash Flow | ||||||
| Free Cash Flow | -11.54M | -8.50M | -8.14M | -24.80M | -15.25M | -7.99M |
| Operating Cash Flow | -11.35M | -8.45M | -7.72M | -15.64M | -14.87M | -7.10M |
| Investing Cash Flow | -2.67M | -2.01M | -798.27K | -13.76M | -21.50K | -826.82K |
| Financing Cash Flow | 15.54M | 14.06M | 5.05M | 12.69M | 35.05M | 7.27M |
Cosmos Holdings Technical Analysis
Negative
0.20
Price Trends
0.22
Negative
0.27
Negative
0.39
Negative
Market Momentum
>-0.01
Negative
46.57
Neutral
16.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Negative. The current price of 0.2 is below the 20-day moving average (MA) of 0.21, below the 50-day MA of 0.22, and below the 200-day MA of 0.39, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.57 is Neutral, neither overbought nor oversold. The STOCH value of 16.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COSM.
Cosmos Holdings Risk Analysis
Cosmos Holdings disclosed 10 risk factors in its most recent earnings report. Cosmos Holdings reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cosmos Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $30.17M | -5.38 | -14.03% | ― | -21.12% | -109.07% | |
55 Neutral | $23.26M | -111.11 | 0.66% | ― | 27.78% | 52.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $12.73M | -0.31 | -96.48% | ― | 29.75% | 37.35% | |
41 Neutral | $284.80K | >-0.01 | -453.74% | ― | ― | ― | |
40 Underperform | $50.64M | -2.77 | -21.10% | ― | 489.78% | 45.39% | |
37 Underperform | $25.33M | -0.55 | -148.91% | ― | -18.24% | -2264.65% |
* Healthcare Sector Average
COSM
Cosmos Holdings
0.21
-0.62
-75.18%
PRPH
Prophase Labs
0.03
-3.09
-99.01%
RMTI
Rockwell Med
7.52
-2.98
-28.38%
TXMD
TherapeuticsMD
2.01
0.85
73.28%
SCYX
SCYNEXIS
5.14
-1.18
-18.67%
AYTU
Aytu BioScience
2.36
0.16
7.27%
Cosmos Holdings Corporate Events
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Cosmos Holdings Shareholders Approve Governance and Equity Changes
Positive
Jul 17, 2026
On July 15, 2026, Cosmos Holdings held its 2026 Annual Meeting, with 28,315,417 of 60,043,491 outstanding common shares represented in person or by proxy, equating to about 47% of eligible voting shares. Shareholders elected all company-nominated ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.